Patents by Inventor Olaf Kinzel

Olaf Kinzel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY
    Publication number: 20230357214
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: February 9, 2023
    Publication date: November 9, 2023
    Inventors: Christian GEGE, Olaf KINZEL, Eva HAMBRUCH, Manfred BIRKEL, Claus KREMOSER, Ulrich DEUSCHLE
  • OXALAMIDE SUBSTITUTED HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR)
    Publication number: 20230108408
    Abstract: The present invention relates to oxalamide substituted heterocyclic compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: April 6, 2023
    Applicant: PHENEX PHARMACEUTICALS AG
    Inventors: Olaf Kinzel, Christoph Steeneck, Marta Czekanska, Sheena Pinto, Ibrahim Murathan Sektioglu, Ulrich Deuschle
  • LXR modulators with bicyclic core moiety
    Patent number: 11618747
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: April 4, 2023
    Assignee: OrsoBio, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
    Patent number: 11078168
    Abstract: The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 3, 2021
    Assignee: Phenex Discovery Verwaltungs-GmbH
    Inventors: Christoph Steeneck, Olaf Kinzel, Simon Anderhub, Martin Hornberger, Gerald Kleymann, Thomas Hoffmann
  • NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY
    Publication number: 20210147398
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: June 28, 2019
    Publication date: May 20, 2021
    Applicant: Phenex-FXR GmbH
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • SPIROCYCLIC COMPOUNDS AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20210122757
    Abstract: The present invention relates to novel spirocyclic compounds which act as modulators of indoleaine 2,3-dioxygenase (IDO1) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dioxygenase. The invention further relates to pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 29, 2021
    Inventors: Olaf KINZEL, Christoph STEENECK, Simon ANDERHUB, Martin HORNBERGER, Sheena PINTO, Barbara HERKERT, Thomas HOFFMANN
  • OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20200352931
    Abstract: The present invention relates to novel compounds which act as modulators of indoleamine 2,3-dioxygenase (IDO1) and to the use of said compounds in the prophylaxis and/or treatment of diseases or conditions mediated by indoleamine 2,3-dioxygenase. The invention further relates to pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 12, 2020
    Applicant: PHENEX DISCOVERY VERWALTUNGS-GMBH
    Inventors: Christoph Steeneck, Olaf Kinzel, Simon Anderhub, Martin Hornberger, Marta Czekanska, Thomas Hoffmann
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 10485795
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 26, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20190292160
    Abstract: The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 3, 2017
    Publication date: September 26, 2019
    Applicant: PHENEX DISCOVERY VERWALTUNGS-GMBH
    Inventors: Christoph Steeneck, Olaf Kinzel, Simon Anderhub, Martin Hornberger, Gerald Kleymann, Thomas Hoffmann
  • Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[?]
    Patent number: 10301272
    Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1?), (100), (100?), (200) and (200?) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: May 28, 2019
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Christian Gege, Christoph Steeneck, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann
  • Novel FXR (NR1H4) binding and activity modulating compounds
    Publication number: 20190142814
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 16, 2019
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 10220027
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 5, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • Trifluoromethyl alcohols as modulators of ROR?t
    Patent number: 10150762
    Abstract: The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R1-1-carbonyl)thiazole-2-carboxamide, wherein R1 is defined in the specification.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 11, 2018
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
  • Thiazoles as modulators of ROR?t
    Patent number: 10080744
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: September 25, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Novel FXR (NR1H4) binding and activity modulating compounds
    Publication number: 20180200243
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 19, 2018
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • FXR (NR1H4) modulating compounds
    Patent number: 9938278
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 10, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Christian Gege, Claus Kremoser, Olaf Kinzel, Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Aaron C. Schmitt, William J. Watkins, Jianjun Xu
  • THIAZOLES AS MODULATORS OF RORyt
    Publication number: 20180064690
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Thiazoles as modulators of ROR?t
    Patent number: 9861618
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 9, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann
  • Trifluoromethyl alcohols as modulators of ROR?t
    Patent number: 9850236
    Abstract: The present invention comprises compounds of Formula I. wherein: X, A1, A2, A3, A4, R1, R2, and R3 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Amide substituted thiazoles as modulators of RORyt
    Patent number: 9845319
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R5, A1, A2, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 19, 2017
    Assignee: Janssen Pharmaceutiuca NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Maud Urbanski, Aihua Wang, David Kummer, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue